SCHEMBL17808696

SCHEMBL17808696

C[C@H]1CC[C@H]2[C@@H]3CCc4cc(OC(C)(C)C)ccc4[C@H]3CC[C@]12C

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 5/20 0.60
HSD17B10 Q99714 5/20 0.60
ESR1 P03372 6/20 0.59
SMN1; SMN2 Q16637 4/20 0.59
ADORA3 P0DMS8 2/20 0.59
ATM Q13315 2/20 0.59
PGR P06401 2/20 0.59
AR P10275 2/20 0.59
SLC6A3 Q01959 2/20 0.59
CHRM1 P11229 1/20 0.59
TBXA2R P21731 1/20 0.59
ADRA1A P35348 1/20 0.59
OPRM1 P35372 1/20 0.59
KDM4E B2RXH2 1/20 0.58
MAPT P10636 4/20 0.57
CYP3A4 P08684 2/20 0.57
TP53 P04637 1/20 0.57
ABCC4 O15439 2/20 0.56
ABCC1 P33527 1/20 0.56
STS P08842 3/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10013340 0.88 LMNA (0.78) LMNAHSD17B10ESR1SMN1; SMN2ADORA3
SCHEMBL10079788 0.87 LMNA (0.77) LMNAHSD17B10ESR1SMN1; SMN2ADORA3
SCHEMBL13015302 0.87 LMNA (0.77) LMNAHSD17B10ESR1SMN1; SMN2ADORA3
SCHEMBL17817390 0.87 LMNA (0.56) LMNAHSD17B10ESR1SMN1; SMN2ADORA3
SCHEMBL16393333 0.85 LMNA (0.59) LMNAHSD17B10ESR1SMN1; SMN2ADORA3
SCHEMBL2610024 0.85 LMNA (0.59) LMNAHSD17B10ESR1SMN1; SMN2ADORA3
SCHEMBL17808702 0.85 ESR1 (0.58) LMNAHSD17B10ESR1SMN1; SMN2ADORA3
SCHEMBL10013350 0.83 ESR1 (0.71) LMNAHSD17B10ESR1SMN1; SMN2ADORA3
SCHEMBL14924236 0.81 ESR1 (0.77) LMNAHSD17B10ESR1SMN1; SMN2PGR
SCHEMBL5265450 0.81 ESR1 (0.77) LMNAHSD17B10ESR1SMN1; SMN2PGR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170370950-A1 BIOTIN CONJUGATES OF ANALYTES CONTAINING AMINO, HYDROXYL, OR THIOL FUNCTIONAL GROUPS FOR USE IN IMMUNODIAGNOSTIC ASSAYS Calbiotech, Inc. 2017-12-28 US disclosed
US-20160161473-A1 BIOTIN CONJUGATES OF ANALYTES CONTAINING AMINO, HYDROXYL, OR THIOL FUNCTIONAL GROUPS FOR USE IN IMMUNODIAGNOSTIC ASSAYS Calbiotech, Inc. 2016-06-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170370950-A1 BIOTIN CONJUGATES OF ANALYTES CONTAINING AMINO, HYDROXYL, OR THIOL FUNCTIONAL GROUPS FOR USE IN IMMUNODIAGNOSTIC ASSAYS SHBG, BTD, CYP24A1 LMNA 2724/4885HSD17B10 584/4885ESR1 52/4885
US-20160161473-A1 BIOTIN CONJUGATES OF ANALYTES CONTAINING AMINO, HYDROXYL, OR THIOL FUNCTIONAL GROUPS FOR USE IN IMMUNODIAGNOSTIC ASSAYS SHBG, BTD, CYP24A1 LMNA 2482/4885HSD17B10 675/4885ESR1 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.